Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Debt / NOTE 0.750% 5/1
-
Market price (% of par)
-
96.98%
-
Total 13F principal
-
$65,515,065
-
Principal change
-
-$34,221,935
-
Total reported market value
-
$63,620,509
-
Number of holders
-
23
-
Value change
-
-$33,301,456
-
Number of buys
-
8
-
Number of sells
-
9
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q3 2022
As of 30 Sep 2022,
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 was held by
23 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$65,515,065
in principal (par value) of the bond.
The largest 10 bondholders included
OAKTREE CAPITAL MANAGEMENT LP, CAPSTONE INVESTMENT ADVISORS, LLC, PALISADE CAPITAL MANAGEMENT LLC/NJ, Voya Investment Management LLC, JPMORGAN CHASE & CO, Russell Investments Group, Ltd., Radcliffe Capital Management, L.P., SCHRODER INVESTMENT MANAGEMENT GROUP, TORONTO DOMINION BANK, and WESTWOOD HOLDINGS GROUP INC.
This page lists
23
institutional bondholders reporting positions
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.